- Home
- USCB vs RZLT Comparison
USCB vs RZLT Comparison
Compare USCB & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USCB
- RZLT
- Stock Information
- Founded
- USCB 2002
- RZLT 2010
- Country
- USCB United States
- RZLT United States
- Employees
- USCB N/A
- RZLT N/A
- Industry
- USCB Major Banks
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- USCB Finance
- RZLT Health Care
- Exchange
- USCB Nasdaq
- RZLT Nasdaq
- Market Cap
- USCB 353.0M
- RZLT 292.0M
- IPO Year
- USCB 2021
- RZLT N/A
- Fundamental
- Price
- USCB $18.20
- RZLT $4.87
- Analyst Decision
- USCB Buy
- RZLT Strong Buy
- Analyst Count
- USCB 4
- RZLT 8
- Target Price
- USCB $16.13
- RZLT $11.63
- AVG Volume (30 Days)
- USCB 26.6K
- RZLT 349.3K
- Earning Date
- USCB 01-23-2025
- RZLT 02-11-2025
- Dividend Yield
- USCB 1.10%
- RZLT N/A
- EPS Growth
- USCB 13.14
- RZLT N/A
- EPS
- USCB 1.04
- RZLT N/A
- Revenue
- USCB $71,791,000.00
- RZLT N/A
- Revenue This Year
- USCB N/A
- RZLT N/A
- Revenue Next Year
- USCB $15.26
- RZLT N/A
- P/E Ratio
- USCB $17.49
- RZLT N/A
- Revenue Growth
- USCB 10.04
- RZLT N/A
- 52 Week Low
- USCB $10.25
- RZLT $0.92
- 52 Week High
- USCB $21.86
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- USCB 53.16
- RZLT 49.47
- Support Level
- USCB $16.01
- RZLT $4.47
- Resistance Level
- USCB $18.42
- RZLT $4.98
- Average True Range (ATR)
- USCB 0.64
- RZLT 0.33
- MACD
- USCB 0.11
- RZLT -0.01
- Stochastic Oscillator
- USCB 81.41
- RZLT 38.10
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.